- ZM241385
-
- $48.00 / 5mg
-
2026-01-14
- CAS:139180-30-6
- Min. Order:
- Purity: 97.02%
- Supply Ability: 10g
- ZM241385
-
- $100.00 / 1KG
-
2022-02-25
- CAS:139180-30-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 100KG
- ZM241385
-
- $100.00 / 1Kg/Bag
-
2022-02-25
- CAS:139180-30-6
- Min. Order: 1Kg/Bag
- Purity: 99%
- Supply Ability: 10kg
|
| | ZM 241385 Basic information |
| Product Name: | ZM 241385 | | Synonyms: | 4-(2-[7-AMINO-2-(2-FURYL)[1,2,4]TRIAZOLO[2,3-A][1,3,5]TRIAZIN-5-YLAMINO]ETHYL)PHENO;Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-;4-(2-[7-AMINO-2-(2-FURYL)[1,2,4]TRIAZOLO[2,3-A][1,3,5]TRIAZIN-5-YLAMINO]ETHYL)PHENOL;ZM 241385;4-(2-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol;CS-2353;ZM 241385; ZM241385; ZM-241385;7-amino-2-(furan-2-yl)-5-[2-(4-hydroxyphenyl)ethyl]amino-[1,2,4]triazolo[1,5-a][1,3,5]triazine | | CAS: | 139180-30-6 | | MF: | C16H15N7O2 | | MW: | 337.34 | | EINECS: | | | Product Categories: | Adenosine | | Mol File: | 139180-30-6.mol |  |
| | ZM 241385 Chemical Properties |
| density | 1.59±0.1 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: >15mg/mL | | pka | 10.03±0.15(Predicted) | | form | powder | | color | white to tan | | InChI | InChI=1S/C16H15N7O2/c17-14-20-15(18-8-7-10-3-5-11(24)6-4-10)21-16-19-13(22-23(14)16)12-2-1-9-25-12/h1-6,9,24H,7-8H2,(H3,17,18,19,20,21,22) | | InChIKey | PWTBZOIUWZOPFT-UHFFFAOYSA-N | | SMILES | C1(O)=CC=C(CCNC2N=C(N)N3N=C(C4=CC=CO4)N=C3N=2)C=C1 |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 46 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | ZM 241385 Usage And Synthesis |
| Uses | ZM 241385 is a selective and potent Adenosine A2A-R antagonist. | | Definition | ChEBI: 4-[2-[[7-amino-2-(2-furanyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol is a diamino-1,3,5-triazine. | | Biochem/physiol Actions | ZM 241385 is a potent selective adenosine A2A antagonist. The A2A receptor plays a role in regulating myocardial oxygen consumption and coronary blood flow and is highly expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release. ZM 241385 has neuroprotective effects and is being investigated for use in Parkinson′s and other neurodegenerative disorders. | | Synthesis | A reaction was carried out in acetonitrile (25 mL) with p-hydroxyphenethylamine (tyramine, 490 mg, 3.75 mmol) and 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine (250 mg, 892 μmol). The reaction mixture was stirred at room temperature for 22 hours. Upon completion of the reaction, the solvent was removed by evaporation and the residue was adsorbed through diatomaceous earth and purified using column chromatography (eluent: dichloromethane/methanol, 25:75, v/v). The target product grade was collected, evaporated to dryness and subsequently recrystallized from ethyl acetate to afford 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)ethyl)phenol (100 mg, 33% yield) as a white solid, melting point: 229-231 °C (literature value: 225- 227°C). The product was analyzed and confirmed by 1H NMR, 13C NMR, high resolution mass spectrometry (HRMS) and high performance liquid chromatography (HPLC).1H NMR (400 MHz, d6-DMSO, 353 K) δ 8.91 (s, 1H), 7.92 (br s, 2H), 7.79 (m, 1H), 7.14 (br t, 1H), 7.04 (m, 3H) , 6.71 (m, 2H), 6.64 (dd, J = 3.3, 1.8 Hz, 1H), 3.49 (m, 2H), 2.78 (m, 2H).13C NMR (101 MHz, d6-DMSO) δ 161.1 (C), 159.0 (C), 155.9 (C), 155.4 (C), 150.1 (C), 146.1 (C), 146.1 (C), 146.1 (C), 146.1 (C), 146.1 (C), 146.1 (C). 146.1 (C), 144.1 (CH), 129.1 (CH), 115.0 (CH), 111.4 (CH), 111.2 (CH), 42.4 (CH2), 33.9 (CH2). HRMS (C16H15N7O2): Calculated value 338.1360 [M + H]+, measured value 338.1353. HPLC : tR 7.34 min, purity 98% (214 nm), 97% (254 nm). | | storage | Room temperature | | References | [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 11, p. 3427 - 3433
[2] Structural Chemistry, 2013, vol. 24, # 4, p. 1241 - 1251
[3] Journal of Medicinal Chemistry, 2015, vol. 58, # 2, p. 718 - 738
[4] Molecular Pharmacology, 1995, vol. 48, # 6, p. 970 - 974
[5] Patent: US5270311, 1993, A |
| | ZM 241385 Preparation Products And Raw materials |
| Raw materials | [(2-furanylcarbonyl)amino]--->LUF5443-->5-Furan-2-yl-3-methyl-1H-[1,2,4]triazole-->2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine-->1H-1,2,4-Triazol-3-amine,5-(2-furanyl)-(9CI)-->Furan-2-carbohydrazide-->2-Furonitrile-->Tyramine |
|